New stock news | Cingulate Biology Hong Kong Stock IPO prospectus invalidated
Wisdom Finance APP learned that the Hong Kong stock prospectus submitted by Jingze Biopharmaceutical (Hefei) Co., Ltd.-B (referred to as Jingze Biopharmaceutical) on December 31, 2025, expired on June 30, 2026, 6 months after submission, with China International Capital Corporation and Guoyuan International as joint sponsors.
Latest
3 m ago

